The world is finding it harder to breathe.
An increasing global incidence of respiratory diseases is driving demand for orally inhaled and nasally delivered medicines. But with greenhouse gas emissions continuing to rise, the pharma industry must consider how to produce much-needed therapies whilst minimising environmental impact.
In the latest issue of OnDrugDelivery, Louise Righton, our Head of Strategic Marketing, and Benedicta Bakpa, Head of ESG, discuss the many aspects involved in driving sustainability in inhaled drug delivery – and how this is shaping the future of the industry.
